Literature DB >> 7133058

The treatment of gram-negative bacteremia and shock.

S M Wolff.   

Abstract

Entities:  

Mesh：

Year:  1982        PMID： 7133058     DOI： 10.1056/NEJM198211113072010

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Once is not enough: clinical trials in sepsis.

Authors:  Daniel A Sweeney; Robert L Danner; Peter Q Eichacker; Charles Natanson
Journal:  Intensive Care Med       Date:  2008-10-07       Impact factor: 17.440

Review 2.  New developments in the treatment of gram-negative bacteremia.

Authors:  M A Jacobson; L S Young
Journal:  West J Med       Date:  1986-02

3.  In vivo and in vitro studies of bacterial endotoxin-membrane interactions and the effects of membrane-active agents.

Authors:  M E Garnett; D V Godin; J M Tuchek
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

4.  Complement activating and opsonic capacity of monoclonal antibodies raised against Escherichia coli O111 and its rough mutant J5.

Authors:  R W Vreede; J Leuvenink; A S Bouter; E C Brouwer; J H Marcelis; J Verhoef
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

5.  Antibodies raised against rough mutants of Escherichia coli and Salmonella strains are opsonic only in the presence of complement.

Authors:  R W Vreede; J H Marcelis; J Verhoef
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

6.  Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Authors:  N N Teng; H S Kaplan; J M Hebert; C Moore; H Douglas; A Wunderlich; A I Braude
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

7.  Studies of the effect of a platelet-activating factor antagonist, CL 184,005, in animal models of gram-negative bacterial sepsis.

Authors:  L W Torley; W C Pickett; M L Carroll; C A Kohler; R E Schaub; A Wissner; S Q DeJoy; A L Oronsky; S S Kerwar
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

8.  Phase I study of a murine monoclonal anti-lipid A antibody in bacteremic and nonbacteremic patients.

Authors:  S Harkonen; P Scannon; R P Mischak; L E Spitler; C Foxall; D Kennedy; R Greenberg
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  Gram-negative shock: approaches to treatment.

Authors:  M A Jacobson; L S Young
Journal:  J R Coll Physicians Lond       Date:  1985-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.